Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy.
Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy.
复制标题
DOI：
10.1371/journal.pone.0071356
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Hoshino T
中科院分区：
文献类型：
--
作者：
Yamashita F;Azuma K;Yoshida T;Yamada K;Kawahara A;Hattori S;Takeoka H;Zaizen Y;Kawayama T;Kage M;Hoshino T
为了改善非小细胞肺癌（NSCLC）患者的预后，需要一种能够预测化疗疗效的生物标志物。本研究的目的是评估EGFR突变和ERCC 1在预测含铂化疗的疗效和NSCLC患者结局中的作用。我们进行了一项回顾性研究，分析接受含铂化疗的NSCLC患者中EGFR突变或ERCC 1表达与无进展生存期（PFS）的关系。采用肽核酸锁核酸聚合酶链反应钳方法检测EGFR突变状态，并采用免疫组化方法检测患者肿瘤标本中ERCC 1的表达。在接受含铂化疗的NSCLC患者中，从不吸烟和外显子19缺失的患者的中位PFS显著更好，从不吸烟、外显子19缺失和女性患者的中位总生存期（OS）显著更好。考克斯回归分析显示19号外显子缺失和从不吸烟与PFS和OS均显著相关;亚组分析显示ERCC 1表达与EGFR突变显著相关，ERCC 1阴性且19号外显子缺失的患者的PFS较长; ERCC 1阳性且19号外显子未缺失的患者的PFS较短。我们的研究结果表明，在接受铂类化疗的NSCLC患者中，19号外显子缺失的患者具有较长的PFS和OS。我们的研究结果表明，铂类化疗对ERCC 1阴性和19号外显子阳性的NSCLC更有效。
In order to improve the outcome of patients with non-small cell lung cancer (NSCLC), a biomarker that can predict the efficacy of chemotherapy is needed. The aim of this study was to assess the role of EGFR mutations and ERCC1 in predicting the efficacy of platinum-based chemotherapy and the outcome of patients with NSCLC. We conducted a retrospective study to analyze the relationships between EGFR mutations or ERCC1 expression and progression-free survival (PFS) in patients with NSCLC who received platinum-based chemotherapy. EGFR mutation status was determined using the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method, and immunohistochemistry was used to examine the expression of ERCC1 in tumor samples obtained from the patients. Among the NSCLC patients who received platinum-based chemotherapy, the median PFS was significantly better in those who had never smoked and those with exon 19 deletion, and the median overall survival (OS) was significantly better in those who had never smoked, those with exon 19 deletion, and women. Cox regression analysis revealed that exon 19 deletion and having never smoked were significantly associated with both PFS and OS. Subset analysis revealed a significant correlation between ERCC1 expression and EGFR mutation, and ERCC1-negative patients with exon 19 deletion had a longer PFS than the other patients; ERCC1-positive patients without exon 19 deletion had a shorter PFS than the other patients. Our results indicate that among NSCLC patients receiving platinum-based chemotherapy, those with exon 19 deletion have a longer PFS and OS. Our findings suggest that platinum-based chemotherapy is more effective against ERCC1-negative and exon 19-positive NSCLC.
登录
查看更多内容
影响因子：
158.5
作者：
Lynch, TJ;Bell, DW;Haber, DA
通讯作者：
Haber, DA
影响因子：
51.1
作者：
Mitsudomi, Tetsuya;Morita, Satoshi;Fukuoka, Masahiro
通讯作者：
Fukuoka, Masahiro
影响因子：
11.2
作者：
Nagai, Y;Miyazawa, H;Hagiwara, K
通讯作者：
Hagiwara, K
影响因子：
5.3
作者：
Kalikaki, Aristea;Koutsopoulos, Anastasios;Voutsina, Alexandra
通讯作者：
Voutsina, Alexandra
影响因子：
20.4
作者：
Lin, Chia-Chi;Hsu, Hsin-Hsin;Mok, Tony
通讯作者：
Mok, Tony